Cardiorespiratory fitness and inflammation among sedentary people with HIV; helping patients increase physical activity; transwomen and metabolic syndrome; failed treatment of precancerous cervical lesions.
Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective? Paul E. Sax, M.D., offers a revised -- and deliberately provocative -- recommendation.
Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.
After years of pressure from prevention advocates, FDA has finally given the other rubber a new name - the internal condom – and a new classification.
The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.
After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Our series on mentor-mentee researchers continues with Ellen Eaton, M.D., and Kelsie Dodson, with the University of Alabama at Birmingham.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
Unmet subsistence needs and clinical outcomes; finding HIV treatment success alongside quality-of-life issues; the potential value of facility-level HIV care continuum data; stimulant use and viral suppression.